Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...

Millions may be suffering from a little-known condition that could be hiding behind common symptoms like heartburn, headaches ...

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

In a new clip posted to Dr Ahmed's Instagram page, the medic said the symptoms, like heartburn, headaches and nausea, can ...

persistent symptoms despite high-dose antihistamine treatment, underscoring the mismatch between the efficacy of antihistamines and the pathophysiology of mast cell activation, according to a review ...

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

Sanofi has announced that it will be expanding its immunology capabilities by acquiring US-based Blueprint Medicines ...

Discover why GERD without esophagitis causes severe symptoms despite normal endoscopy results. Learn 8 hidden mechanisms ...

By focusing on common symptoms upfront ... the KIT D816V mutation – the primary driver of SM and other clonal mast cell diseases – relative to the general population. Educating HCPs on ...